dm+d

Unassigned

New Medicines

PD-L1-positive metastatic non-small cell lung cancer (NSCLC) - first-line in patients in whom EGFR-, ALK- or ROS1-directed therapy is not indicated as primary therapy

Information

New molecular entity
Merck Sharp & Dohme (MSD)
Merck & Co (name used in US for MSD)

Development and Regulatory status

None
Phase III Clinical Trials
Phase III Clinical Trials

Category

Pembrolizumab is a humanised monoclonal IgG4 anti-PD-1 antibody with a high affinity for PD-1 and with pure antagonist properties. Vibostolimab is a humanised monoclonal antibody that binds to the T-cell immunoreceptor with immunoglobulin and ITIM domains (TIGIT), thereby blocking the interaction between TIGIT and its ligands, which, in turn, activates T lymphocytes. Coformulation comprises pembrolizumab 200mg and vibostolimab 200mg given every 3 weeks (Q3W) for up to 35 cycles (up to ~2 years).
In 2018, around 35,000 people were estimated to be diagnosed with NSCLC in England. Lung cancer falls into 2 main histological categories: around 85–90% are NSCLC and the remainder are small cell lung cancers [1].
PD-L1-positive metastatic non-small cell lung cancer (NSCLC) - first-line in patients in whom EGFR-, ALK- or ROS1-directed therapy is not indicated as primary therapy
Intravenous infusion